Publications

Scientific Publications

 

2024

• Freeze, Robert, Philip Hughes, Timothy Haystead, and Scott Scarneo. "Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical Models." Journal of Pain Research (2024): 2287-2298.
• Damhofer, Helene, Tülin Tatar, Benjamin Southgate, Scott Scarneo, Karl Agger, Daria Shlyueva, Lene Uhrbom et al. "TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers." Cell Death & Disease 15, no. 4 (2024): 273.

2023

• Freeze, Robert, Kelly W. Yang, Timothy Haystead, Philip Hughes, and Scott Scarneo. "Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis." Pharmacology Research & Perspectives 11, no. 4 (2023): e01124.
• Scarneo, Scott, Xin Zhang, Yaomin Wang, Jose Camacho-Domenech, Jennifer Ricano, Philip Hughes, Tim Haystead, and Andrea G. Nackley. "Transforming growth factor-β-activated kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain." The journal of pain 24, no. 9 (2023): 1633-1644.
• Bale, Swarna, Priyanka Verma, Bharath Yalavarthi, Scott Arthur Scarneo, Philip Hughes, M. Asif Amin, Pei-Suen Tsou et al. "Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis." JCI insight 8, no. 14 (2023).

2022

• Scarneo, Scott, Philip Hughes, Robert Freeze, Kelly Yang, Juliane Totzke, and Timothy Haystead. "Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis." ACS Chemical Biology (2022).

2020

• Scarneo, S. A., Hughes, P. F., Yang, K. W., Carlson, D. A., Gurbani, D., Westover, K. D., & Haystead, T. A. (2020). A highly selective inhibitor of interleukin-1 receptor–associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. Journal of Biological Chemistry, 295(6), 1565-1574.
• Totzke, J., Scarneo, S. A., Yang, K. W., & Haystead, T. A. (2020). TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biology, 10(9), 200099.
• Scarneo, S. A., Yang, K. W., Roques, J. R., Dai, A., Eibschutz, L. S., Hughes, P., & Haystead, T. A. (2020). TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. Oncotarget, 11(21), 1961.

2019

• Scarneo, S. A., Eibschutz, L. S., Bendele, P. J., Yang, K. W., Totzke, J., Hughes, P., ... & Haystead, T. A. (2019). Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis research & therapy, 21(1), 1-10.

2018

• Scarneo, S. A., Mansourati, A., Eibschutz, L. S., Totzke, J., Roques, J. R., Loiselle, D., ... & Haystead, T. A. (2018). Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific reports, 8(1), 1-11.

2017

• Totzke, J., Gurbani, D., Raphemot, R., Hughes, P. F., Bodoor, K., Carlson, D. A., ... & Derbyshire, E. R. (2017). Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-α inhibition for cancer and autoimmune disease. Cell chemical biology, 24(8), 1029-1039.